Sabrina McCrear

CMS finalized Transparency in Coverage updates as a researcher warns ghost rates and missing inpatient data limit payer price files.

Geoffrey Chupp, MD, explains how IL-5 and IL-4Rα biologics are reshaping COPD care and why eosinophil requirements still limit access.

Michael Wechsler, MD, MMSc, explains how anti-IL-5 therapies studied in the MIRRA and MANDARA trials are reducing steroid use in EGPA.

Jeffery A. Goad, PharmD, MPH, of Chapman University explains why pharmacists are trusted, accessible sources for COVID-19 vaccine questions.

Michael Wechsler, MD, of National Jewish Health, discusses how twice yearly depemokimab reduces exacerbation risk in patients with T2 asthma.

Geoffrey Chupp, MD, of Yale Medicine explains how a blood RNA study shows T2-low asthma is more complex than clinicians generally think.

Without a functioning ACIP, Jeffery Goad, PharmD, MPH, explains who now guides COVID-19 vaccine use and how HMOs can stock vaccines.

Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.

As US measles cases top 3600, Christina Madison, PharmD, explains how pharmacists can counter vaccine misinformation and rebuild trust.

FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs

Gay and bisexual men make up 79.8% of new HIV diagnoses; Christina Madison, PharmD, on why trusted messengers matter.

Kevin Astle, PharmD, on how pharmacies can reach young men unaware of their HIV status and why step therapy limits PrEP.

CDC's David A. Siegel, MD, MPH, on rising cancer diagnoses, falling deaths, and where CDC's cancer control resources go next.

CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.

Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine

Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.

Overlapping COVID-19 and flu symptoms make diagnosis hard, says Trinity Health's Tammy Lundstrom, who outlines prevention and vaccine guidance.

CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.

A bioethicist explains why Kalshi's new FDA approval and clinical trial betting markets raise concerns about bias, herd behavior, and insider trading.

All 50 states have applied for CMS's GENEROUS Model, a Medicaid drug pricing program expected to save $64.3 billion over the next decade.

Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.

Keith Kaye, MD, MPH, explains how shorter antibiotic courses and optimized dosing help balance treatment efficacy against C. diff risk.

Experts at ERS Congress 2026 discuss why attending respiratory conferences drives learning, networking, and better patient outcomes.

Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.

Nicola Hanania, MD, discusses why delayed dupilumab initiation after an asthma exacerbation raises costs and outcomes risk.

Real-world COPD data from ERS 2026 support RSV vaccination, but Jorgen Vestbo, MD, says cost remains the biggest barrier to wider uptake.

Timely dupilumab initiation after a severe asthma exacerbation lowered costs vs delayed treatment, ERS 2026 data show.

Jason Pogue, PharmD, breaks down which antibiotic classes carry the highest C. diff risk and why treatment duration matters just as much.

Francesca Polverino, MD, PhD, says COPD care still lacks a true precision medicine approach.

Keith Kaye, MD, MPH, breaks down the institutional gaps, from antibiotic overuse to hand hygiene fatigue, that let Clostridioides difficile persist.